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Abstract
Background: In the rural areas of sub-Saharan Africa, the majority of young children affected by malaria have no access
to formal health services. Home treatment through mothers of febrile children supported by mother groups and local
health workers has the potential to reduce malaria morbidity and mortality.
Methods: A cluster-randomized controlled effectiveness trial was implemented from 2002–2004 in a malaria endemic
area of rural Burkina Faso. Six and seven villages were randomly assigned to the intervention and control arms
respectively. Febrile children from intervention villages were treated with chloroquine (CQ) by their mothers, supported
by local women group leaders. CQ was regularly supplied through a revolving fund from local health centres. The trial
was evaluated through two cross-sectional surveys at baseline and after two years of intervention. The primary endpoint
of the study was the proportion of moderate to severe anaemia in children aged 6–59 months. For assessment of the
development of drug efficacy over time, an in vivo CQ efficacy study was nested into the trial. The study is registered
under http://www.controlled-trials.com (ISRCTN 34104704).
Results: The intervention was shown to be feasible under program conditions and a total of 1.076 children and 999
children were evaluated at baseline and follow-up time points respectively. Self-reported CQ treatment of fever episodes
at home as well as referrals to health centres increased over the study period. At follow-up, CQ was detected in the
blood of high proportions of intervention and control children. Compared to baseline findings, the prevalence of anaemia
(29% vs 16%, p < 0.0001) and malaria parameters such as prevalence of P. falciparum parasitaemia, fever and palpable
spleens was lower at follow-up but there were no differences between the intervention and control group. CQ efficacy
decreased over the study period but this was not associated with the intervention.
Discussion: The decreasing prevalence of malaria morbidity including anaemia over the study period can be explained
by an overall increase of malaria prevention and treatment activities in the study area. The lack of effectiveness of the
intervention was likely caused by contamination, pre-existing differences in the coverage of malaria treatment in both
study groups and an unexpectedly rapid increase of resistance against CQ, the first-line treatment drug at the time of
the study.
Published: 25 March 2008
Malaria Journal 2008, 7:50 doi:10.1186/1475-2875-7-50
Received: 3 December 2007
Accepted: 25 March 2008
This article is available from: http://www.malariajournal.com/content/7/1/50
© 2008 Kouyaté et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Malaria Journal 2008, 7:50 http://www.malariajournal.com/content/7/1/50
Page 2 of 13
(page number not for citation purposes)
Background
At least one million annual malaria deaths occur among
young children in rural sub-Saharan Africa (SSA). Most of
these deaths are in populations with little access to health
services [1-4] In such areas, home treatment with chloro-
quine (CQ), antipyretics and traditional remedies is the
most frequent response of caretakers to fever episodes in
children [4-6]. However, due to the increasing resistance
against CQ in most countries in SSA together with limited
access to modern health services, poor quality of such
services, low compliance with treatment schemes and
poor quality of drugs sold at markets, the community
effectiveness of malaria treatment is very low [6-13].
As malaria treatment provided through formal health
services is currently not a sufficiently effective strategy for
malaria control in rural SSA, interventions aiming at
improving malaria home treatment by main caretakers,
usually the mothers, may be considered as a complemen-
tary strategy. There is some evidence that improved home
management of malaria in young children of SSA will
result in earlier and more effective treatment with conse-
quently reduced morbidity and mortality [14,15].
This project is an EU INCO-DEV funded collaboration
between the Heidelberg University (Germany), Karolin-
ska Institute (Sweden), Muhimbili University College of
Health Sciences (Tanzania) and Centre de Recherche en
Santé de Nouna (Burkina Faso) called MAMOP project
(Improving the management of childhood MAlaria: an
experiment to bridge the gap between MOthers and
health care Providers). It is a controlled malaria commu-
nity intervention with a pre-post design conducted in
rural Burkina Faso and Tanzania in 2002 – 2004. The
overall objective of the MAMOP study was to evaluate the
feasibility and effectiveness of an intervention aimed at
improving case management of malaria in underfive chil-
dren through primary caretakers in collaboration with
local women groups and existing health centres.
Methods
Study area
The study was implemented in the rural part of the
research zone of the Centre de Recherche en Santé de
Nouna (CRSN) in Nouna Health District, north-western
Burkina Faso (Figure 1). The Nouna area is a dry orchard
savannah, populated mainly by subsistence farmers of dif-
ferent ethnic groups. Malaria is holoendemic but highly
seasonal, and the transmission intensity varies between
100 and 1000 infective bites per person and year between
study villages [16,17]. Formal health services in the study
area are provided by a limited number of rural health cen-
tres and the district hospital in Nouna town [18]. Village-
based health centres are usually equipped with two nurses
and one mid-wife and do outreach work in the surround-
ing 7–10 villages under their responsibility. Malaria con-
trol is mainly based on home treatment with CQ, which
has been shown to be still sufficiently effective in 2001,
and on malaria prophylaxis for pregnant women
[4,19,20]. Untreated mosquito nets have been used in the
area for a long time, but insecticide-treated nets (ITN)
were only recently introduced in the frame of an effective-
ness study [21,22]. Communities in the study area have
been shown to be quite well organized with regard to risk
sharing mechanisms. In particular women groups with a
focus on mutual agricultural support traditionally exist in
all villages [23].
Study design
The study was designed as a cluster-randomized control-
led effectiveness trial. Using the data base of the Nouna
Demographic Surveillance System (DSS) [24], villages
were selected by lottery (OM, AJ) until an approximate
sample size of 1.200 households per study arm was
achieved. As a result, six (Pa, Toni, Kemena, Denissa-
Mossi, Boune, Lekuy) and seven (Bankoumani,
Kamadena, Labarani, Barakuy, Dankoumana, Soulemana,
Tissi) villages were randomly assigned to the intervention
and control arms respectively (Figure 2).
The primary outcome of the study was the proportion of
moderate to severe anaemia (haematocrit ≤ 24%) in chil-
dren aged 6 to 59 months. Secondary outcomes were
prevalences of fever, malaria, of palpable spleens (Hackett
score ≥ 2), of other illnesses, mean species-specific
number of blood films positive for malaria parasites,
mean species-specific malaria parasite densities, mean
haematocrit values and mean weight. Finally, in vivo CQ
efficacy was measured in all study children with uncom-
plicated falciparum malaria at baseline and at follow-up
using a modified version of the standard WHO protocol
[25].
To be able to detect a 10% difference in anaemia preva-
lence between the intervention and control group with
80% power and at a significance level of 5%, and assum-
ing a prevalence in the control group of 20%, and a con-
servative design factor of 2.5, 992 under-five children
were required [26]. As the households were used as units
of analysis and as around 80% of all households include
an under-five child, about 1200 households had to be
sampled.
The intervention
The intervention was targeted at three groups: health
workers (nurses) from five peripheral health centres
(Toni, Dara, Bourasso, Lekuy, Koro), women group lead-
ers, and the main care takers (usually the mothers) of pre-
school children. The community members of the six
intervention villages selected a total of 70 women group
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leaders, two by sub-village (sub-village numbers ranged
from 3–9 per village). Inclusion criteria for group leaders
used by the communities were permanent residency in the
sub-village, age 30–50 years, honesty, and respect by the
community. The main components of the intervention
were:
• Training of health staff, women group leaders and moth-
ers
• Sensitisation of the communities
• Drug supply to women group leaders, revolving fund
• Supervision of health workers and women group leaders
• Intervention information system.
A five days training course for the health workers of par-
ticipating health centres was conducted by one of the
investigators (FS) together with the District Medical
Officer and included an update on malaria case manage-
ment and an introduction to adult non formal education
methods. Afterwards, all women group leaders were
trained in respective peripheral health centres by the
health workers under the supervision of the investigators
for two days on all relevant aspects of malaria knowledge
and management including referral criteria. The training
Map of Burkina FasoFigure 1
Map of Burkina Faso.
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included discussions as well as practical sessions using
locally produced pictorial sensitisation material and role
play, with one refresher course over the study period (Fig-
ures 3, 4, 5). After this was completed, a sensitisation cam-
paign was done in all intervention villages. Thereafter, the
women group leaders under the supervision of their local
health workers trained an average of 15 mothers for half a
day in their sub-villages on correct malaria management.
All women group leaders were regularly provided with CQ
and paracetamol from the essential drug stock of Nouna
Health District. Pre-packed tablets have been shown to be
better for ensuring compliance compared to loose tablets
in African countries including Burkina Faso [14,27,28].
Thus, CQ and paracetamol were pre-packed in plastic bags
in four age-specific doses (0 – 6 months, 7 – 11 months,
1 – 3 years, 4 – 5 years) each with a specific colour and
containing pictorial guidelines according to national
malaria treatment guidelines (Figures 3, 4, Table 1).
Mothers with febrile children were advised to go to the
house of women group leaders for early treatment. Chil-
dren were treated with a total dose of 25 mg/kg CQ over a
period of three days (first and second day: 10 mg/kg, third
day: 5 mg/kg). In addition, all children received standard
doses of paracetamol (10 mg/kg every 12 hours) over the
Map of the Nouna study areaFigure 2
Map of the Nouna study area.
Malaria Journal 2008, 7:50 http://www.malariajournal.com/content/7/1/50
Page 5 of 13
(page number not for citation purposes)
first two days. Women group leaders were advised to
directly supervise the first dose of CQ and paracetamol,
and to visit the sick child again on the second and third
day. In case of danger signs at any time point or ongoing
fever at the end of the treatment time, the women group
leaders had to refer the child to the health centre.
At the beginning of the intervention, a six months stock of
drugs was provided free of charge to the women group
leaders, who had to afterwards renew their stock by buy-
ing new drugs from the health workers. Drugs were sold
by the women group leaders to the mothers/caretakers at
prices which allowed them to make a small profit as an
incentive (table 1). The health workers visited the sub vil-
lages monthly for supervision with a standardized check-
list, collection of forms and for drug provision. Overall
supervision and if necessary – specific support – was car-
ried out by the investigators every month for the first three
months and thereafter every three months.
The intervention was monitored through a specific inter-
vention information system which used forms based on
pictorial charts, which were filled in every month by the
women group leaders (figure 5). The first form collected
information on (1) the number of malaria cases managed,
(2) the number of home visits done, (3) the number of
cases referred to the health facilities, (4) the number of
children who had visited the health facilities, and (5) the
number of children who had died. The second form
reported the time between illness onset and initiation of
the treatment. The third form reported the number of pre-
packaged drug bags used for each age group every month.
Information about the process of the intervention in
health facilities was gathered through specific data collec-
tion tools (supervision report, pre-packaged drugs inven-
tory list) as well as through the routine health information
system (health centres registers, patients clinical files,
referrals and counter referrals sheets).
The intervention had been pre-tested in three villages out-
side the study area. For the main study, training of health
staff and women group leaders took place from February
until June 2003. The intervention itself was fully imple-
mented from July 2003 until October 2004, thus covering
two rainy seasons.
Study evaluation
A baseline survey took place in September/October 2002,
and a follow-up survey in September/October 2004.
All households with children below 5 years of age were
included into the two surveys. In households with more
than one eligible child, the survey child was chosen by lot-
tery. All survey children were examined by the study phy-
sician (FS). Children found ill during the surveys were
treated according to national guidelines. Those fulfilling
the criteria for uncomplicated falciparum malaria (fever +
≥ 5.000 Plasmodium falciparum parasites per μl) were fol-
lowed up for in vivo drug efficacy testing over a two weeks
period. The WHO definitions for early treatment failure
(ETF), late clinical failure (LCF), late parasitological fail-
ure (LPF) and adequate clinical and parasitological
response (ACPR) were applied [25].
All children included into the in vivo drug efficacy study
received standard doses of CQ and paracetamol over three
days. Administration of study medications was directly
supervised by the study team on day 0 and by village-
based field workers on day 1 and day 2. In case of vomit-
ing within one hour after the study medication, the med-
ication was repeated. No drugs were allowed as
concomitant treatment. Over the 14 days follow-up
period, study children were seen daily by the field work-
ers, who checked them for danger signs, measured their
Pictoral chart example: referral of severely sick children to the he lth centreFigu e 3
Pictoral chart example: referral of severely sick children to 
the health centre.
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axillary temperature with a thermometer, and took finger
prick blood samples. In case of clinical or parasitological
failure, children were given single-dose pyrimethamine-
sulfadoxine rescue treatment (taken from the essential
drug store of Nouna Health District) according to
national guidelines. Children with danger signs were
referred to the health centre.
Treatment procedures were followed through documenta-
tion of self-reported behaviour during surveys as well as
through CQ determination in blood samples.
Laboratory investigations
From all children seen at the baseline and follow-up sur-
vey, a finger-prick blood sample was taken. From this,
thin and thick blood smears were prepared for malaria
diagnosis while anaemia determination was done
through measurement of haematocrit values with a porta-
ble microhaematocrit centrifuge (Compur Microspin,
Bayer Diagnostics, Germany).
For those children included into the CQ efficacy study,
additional finger-prick blood samples were taken on day
2, day 3, day 7, day 14, and on any other day the child pre-
sented with symptoms during follow up according to
standard procedures [25]. Moreover, pre-treatment filter
Pictoral chloroquine treatment guidelines by age groupFigu e 4
Pictoral chloroquine treatment guidelines by age group.
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paper blood samples were taken from every child and ran-
domly distributed in equal proportions for determination
of chloroquine content and chloroquine resistance mark-
ers. Concentration of chloroquine and its metabolite
desethylchloroquine were measured using high pressure
liquid chromatography at Karolinska Institute in Stock-
holm.
Blood films were kept in closed slide boxes until they were
transported to the CRSN laboratory in Nouna town. After
Giemsa-staining, all films were examined by experienced
laboratory technicians. Thick and thin blood films were
analysed for the species-specific parasite density per μl by
counting against 200 white blood cells and multiplying
by 50. Slides were declared negative if no parasites were
seen in 400 fields on the thick film. For quality control a
10% random sample of blood films is regularly cross
checked at the laboratory of the Heidelberg School of
Tropical Medicine [21].
Statistical analysis
To assess the effect of the intervention, logistic regression
was used. In separate models, anaemia (haematocrit ≤
24%), fever (≥ 37.5°C), spleen enlargement (Hackett
score ≥ 2), clinical malaria (fever + ≥ 5000 parasites/μl),
and malaria parasitaemia (>0 parasites/μl) were consid-
ered as binary outcomes. Age (continuous), weight (con-
tinuous) and ethnic group (4 groups: Bobo, Dafing,
Mossi, other) were considered as co-variables for adjust-
Pictoral chart example: intervention information systemFigu e 5
Pictoral chart example: intervention information system.
Table 1: Drug package (chloroquine + paracetamol) prices by 
provider and age group
Age groups Prices to women leaders Prices to caretakers
0 – 6 months 15 FCFA (0.03 US $) 30 FCFA (0.06 US $)
7 – 11 months 20 FCFA (0.04 US $) 40 FCFA (0.08 US $)
1 – 3 years 30 FCFA (0.06 US $) 60 FCFA (0.12 US $)
4 – 5 years 40 FCFA (0.08 US $) 80 FCFA (0.16 US $)
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ment in the model. The distribution of the outcome vari-
ables in intervention and control group was compared at
baseline to check adequacy of randomization. Fisher exact
test was used to compare rates. The analysis was per-
formed with SAS release 8.02 (SAS® Institute Inc, Cary,
NC, USA).
Ethical aspects
The protocol was approved by the local Ethics Committee
in Burkina Faso. Community consent was sought during
village meetings in all study villages. During the following
visits to individual households, caretakers were asked for
their oral consent after having received detailed informa-
tion from the study physician about all risks and benefits
of the study. They were clearly informed that they could
withdraw from the study at any time and without disad-
vantage. All children in the specified age group found to
be ill during cross-sectional surveys or during follow-up in
case of the CQ resistance study received free treatment in
the village or were referred to Nouna hospital if indicated.
Results
Study group characteristics
A total of 1,083 children (542 from intervention and 541
from control villages) and a total of 1006 children (496
from intervention and 510 from control villages) were
included into the study at baseline and follow-up time
points respectively (Figure 6).
Table 2 shows demographic characteristics of children
from both study groups at baseline and follow-up time
points. Comparing children from intervention and con-
trol clusters at baseline and follow-up, there were no sig-
nificant differences with regard to age and sex. However,
intervention and control clusters differed much with
regard to the presence of the Bobo and Marka ethnicity.
Comparing children from the intervention and control
clusters over time, the samples did not differ significantly
with the exception of follow-up children having been
slightly older in both groups at follow-up.
MAMOP study flow chartFigure 6
MAMOP study flow chart.
Study children
N=2.089
Baseline survey
N=1.083
Follow-up survey
N=1006
Intervention
N=542
Control
N=541
Intervention
N=496
Control
N=510
Table 2: Demographic, clinical and parasitological characteristics of study children at baseline and follow-up time points.
Baseline survey Baseline survey Follow-up survey Follow-up survey
Intervention (n = 542) Control (n = 541) Intervention (n = 496) Control (n = 510)
Ethnicity (%)
Marka 99 (18) 312 (58) 100 (20) 305 (60)
Bobo 301 (56) 116 (21) 280 (56) 96 (19)
Peulh 33 (6) 35 (6) 17 (3) 35 (7)
Mossi 81 (15) 51 (9) 79 (16) 44 (9)
Samo 18 (3) 21 (4) 13 (3) 26 (5)
Other 10 (2) 6 (1) 7 (1) 4 (1)
Median age (months) 31 30 35 35
Median age (range) (5–56) (4–56) (5–60) (5–60)
Male/female 285/257 266/275 238/258 267/243
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A total of 114 children (68 from intervention and 46 from
control villages) and a total of 181 children (88 from
intervention and 93 from control villages) were included
into the CQ efficacy study at baseline and follow-up time
points respectively (Figure 7). The difference in number of
children from this sub-study at baseline and follow-up is
explained by the fact that for logistical reasons, the recruit-
ment of children at baseline was only in four villages (two
intervention, two control), while at follow-up, it was in
nine villages (five intervention, four control). All four vil-
lages sampled at baseline were again sampled at follow-
up. There were no major differences in baseline demo-
graphic, clinical or parasitological characteristics between
survey children (Table 3). All study children completed
the 14 days follow-up.
Compliance with the intervention
Some 12.500 pre-packaged malaria treatments were sold
in the intervention villages over the period July 2003 until
October 2004. Table 4 shows the data on self-reported
compliance in study children during baseline and follow-
up surveys. The number of self-reported fever episodes
(fever during last two days) was lower during the baseline
survey compared to the follow-up survey (29% vs 52%),
without differences between study groups. At baseline,
more children in the control villages compared to inter-
vention villages reported having treated these fever epi-
sodes with CQ at home (64% vs 35%), but this was
reversed at follow-up (60% vs 72%). At follow-up,
women group leaders were reportedly consulted for the
management of CQ home treatment episodes in 88% in
the intervention group but also in 9% of the control
group. The proportion of fever episodes treated at formal
health services was very low at baseline and increased over
Chloroquine efficacy study flow chartFigu e 7
Chloroquine efficacy study flow chart.
Study children
N=295
Baseline survey
N=114
Follow-up survey
N=181
Intervention
N=68
Control
N=46
Intervention
N=88
Control
N=93
Day 14
N=68
Day 14
N=46
Day 14
N=88
Day 14
N=93
Table 3: Demographic, clinical and parasitological characteristics of children included into the chloroquine efficacy study at baseline 
and follow-up time points
Baseline survey Baseline survey Follow-up survey Follow-up survey
Intervention (n = 68) Control (n = 46) Intervention (n = 88) Control (n = 93)
Mean age, range (months) 30.1; 6–58 33.5; 12–60 25.1; 6–58 27.7; 6–58
Male 35 21 46 45
Mean weight, range (kg) 11.1; 6.5–16.9 11.2; 5.9–17.3 10.1; 5.9–18.3 10.3; 5–16
Mean temperature, range (°C) 38.0; 37.5–39.5 38.0; 37.5–39.4 38.1; 37.5–40.1 38.2; 37.5–40.5
Mean number P. falciparum trophozoites, range 19.826, 5.000–67.000 24.541; 5.000–158.000 33.448; 5.000–174.500 21.063; 5.000–101.000
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the study period (2% vs 11%). There were no differences
in this treatment pattern at baseline (2% vs 2%), but the
increase was higher in the intervention compared to the
control villages during follow-up (15% vs 8%).
Due to technical problems, no measurements of CQ
blood levels were possible during the baseline survey.
During the follow-up survey, CQ was detected in the
blood of 33/43 (77%) and 37/43 (86%) while the
median CQ blood level (range) was 212 nmol/L
(23–26.878) and 407 (23–13.734) nmol/L in interven-
tion and control group children respectively.
Effects of the intervention on primary and secondary 
outcomes
Table 5 gives the primary and secondary study outcomes
except the CQ efficacy results. The prevalence of anaemia,
fever, splenomegaly and P. falciparum parasitaemia but
not of falciparum malaria was significantly lower during
the follow-up compared to the baseline survey, but there
were no significant differences between intervention and
control group. A multivariate analysis showed no effect of
the intervention on any of the outcome variables consid-
ered. However, there was a highly significant improve-
ment regarding the prevalence of anaemia, fever, malaria,
P. falciparum parasitaemia and splenomegly at the follow-
up survey independent of the intervention (p < 0.001).
The results of the in vivo CQ efficacy study are given in
table 6. At baseline, the overall day 14 ACPR was 76/114
(67%), without differences between children from inter-
vention and control villages. At follow-up, an ACPR
occurred in 46/88 (52%) of intervention group children
and in 41/93 (44%) of control group children. After con-
trolling for baseline variables, there was a significant effect
of time (OR 0.4, 95% CI 0.2–0.7), but not of the interven-
tion (OR 1.4, 95% CI 0.8–2.5) on ACPR.
Discussion
This study was designed as a cluster-randomized control-
led trial with a sufficient sample size to show intervention
effects of public health importance on malaria parame-
ters. The intervention was shown to be feasible under pro-
gramme conditions and the uptake was documented by
an increase of malaria treatment with CQ in the interven-
tion households and by an increase of referrals to the local
health centres. Unfortunately, at baseline the use of CQ
was higher in the control compared to the intervention
villages which points to the fact that intervention and con-
trol area differed with regard to treatment behaviour.
However, although CQ treatment increased in the inter-
Table 4: Self-reported treatment procedure information in study children during baseline and follow-up surveys
Baseline survey Baseline survey Follow-up survey Follow-up survey
Intervention (n = 542) Control (n = 541) Intervention (n = 496) Control (n = 510)
Fever last 2 days (%) 179/542 (33) 132/541 (24) 241/496 (49) 282/510 (55)
Treatment of fever episode
- with CQ at home (%) 62/179 (35) 85/132 (64) 172/241 (72) 168/282 (60)
- at health centre (%) 4/179 (2) 2/132 (2) 36/241 (15) 23/282 (8)
Involvement of women group leaders in CQ treatment - - 151/172 (88) 15/168 (9)
Table 5: Effects of the intervention on study outcomes
Baseline survey Baseline survey Follow-up survey Follow-up survey p§
Intervention (n = 542) Control (n = 541) Intervention (n = 496) Control (n = 510)
Anaemia* (%) 152 (28) 162 (30) 83 (17) 74 (15) 0.32
Fever prevalence** (%) 201 (37) 189 (35) 143 (29) 142 (28) 0.40
Falciparum malaria prevalence*** (%) 87 (16) 85 (16) 64 (13) 71 (14) 0.45
Spleen enlargement**** (%) 108 (20) 79 (15) 22 (4) 19 (4) 0.08
P. falciparum parasitaemia (%) 455 (84) 438 (81) 379 (76) 366 (72) 0.05
Range 80–100.000 40–129.000 50–180.000 100–108.000
Median P. falciparum 5.000 5.000 3.000 3.000
Median haematocrit (range) 28 (12–40) 28 (14–40) 30 (16–42) 30 (10–40)
Median weight (kg) 11.2 11.1 11.1 11.6
* haematocrit ≤ 24%, ** ≥ 37.5°C, *** ≥ 37.5°C + ≥ 5.000 parasites/μl, ****Hackett ≥ 2, § p-value for effect of intervention on study outcomes 
adjusted for time, age, weight and ethnic group
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vention villages it was observed to a similar degree in the
control villages. This is to a large degree explained by the
high degree of pre-existing CQ treatment in control vil-
lages. Moreover, contamination could have occurred by
communication between the villagers of both study arms
but also by local health workers who partly were respon-
sible for both intervention and control villages. Such an
interpretation is also supported by the fact that some 10%
of women in control villages also received support from
women group leaders. A further explanation for the high
degree of CQ treatment in the control villages is a possible
contamination by a parallel community-based CQ-distri-
bution project in the area. In this GTZ (Gesellschaft für
Technische Zusammenarbeit) – supported reproductive
health project, women of 18 villages neighbouring the
MAMOP study area received contraceptives but also CQ
through trained volunteers. This unforeseen additional
contamination has likely contributed to making the con-
trol zone not a real control zone.
The main findings from the study were significant reduc-
tions in the prevalence of anaemia, P. falciparum parasitae-
mia and spleen enlargement over time, but without
differences between study groups. The differences in the
prevalence of anaemia and malaria parameters between
the baseline survey in 2002 and the follow-up survey in
2004 are likely caused by a higher use of CQ in the study
area. This hypothesis is supported by the finding of high
CQ blood levels both in intervention and control children
during follow-up. However, the effects of another com-
munity based malaria study which was implemented in
all villages of the rural CRSN study and during which all
newborn children received insecticide-treated mosquito
nets (ITN) free of charge may also play a role in this over-
all dynamic [21]. As the enrolment of such study children
took place from mid-2000 until the end of 2002, increas-
ing protection of under five children with ITN is a likely
additional explanation for the observed reductions of
malaria morbidity in both the intervention and control
villages of the MAMOP study. However, the design and
conduct of the ITN trial makes it very unlikely that there
was a differential effect on the MAMOP study groups.
Moreover, the observed differences in malaria parameters
between the two surveys may also be explained by differ-
ences in malaria transmission intensities due to annual
variations in the pattern and amount of rainfall.
Another important observation from this study is the sig-
nificant increase in clinically relevant CQ resistance in the
study area over the two years observation period. This
finding supports similar findings from a number of other
studies which looked at the efficacy of CQ in Burkina Faso
in recent years [18,19]. However, the fact that a more
intense CQ drug pressure in the intervention villages was
not associated with a more rapid increase of in vivo CQ
resistance lends support to the hypothesis that better com-
pliance with the full course of antimalarial treatment will
likely delay resistance development [12,29].
Obviously, all-cause mortality and cause-specific mortal-
ity would have been the best outcome measure for this
kind of intervention study. Due to sample size considera-
tions and costs moderate to severe anaemia was chosen as
the primary endpoint. The MAMOP community interven-
tion had no effect on the prevalence of anaemia. This
could at least partly be explained by the finding from
another cohort study in the rural CRSN study area which
has demonstrated that malnutrition but not malaria is the
main determinant of anaemia development in young chil-
dren of the area [30]. However, as the MAMOP study
showed also no effects on other malaria parameters the
likely explanation is that the intervention was simply not
effective due to contamination, pre-existing differences in
the coverage of malaria treatment in both groups and the
unexpected rapid development of CQ resistance in the
area.
Only a few studies have tried to measure the effects of
complex malaria treatment interventions at the commu-
nity level in endemic areas. One study in Ethiopia has
measured the effectiveness of treating malaria episodes of
young children through their mothers on mortality and
was able to show a major reduction in all-cause mortality
and malaria-specific mortality attributed to the interven-
Table 6: Chloroquine efficacy in young children of rural Burkina Faso in intervention and control communities
Baseline survey Baseline survey Follow-up survey Follow-up survey p-value*
Intervention (n = 68) Control (n = 46) Intervention (n = 88) Control (n = 93)
ETF (%) 8 (12) 3 (7) 13 (15) 12 (13) 0.88
LCF (%) 4 (6) 5 (11) 4 (5) 13 (14) 0.04
LPF (%) 11 (16) 7 (15) 25 (28) 27 (29) 0.99
ACPR (%) 45 (66) 31 (67) 46 (52) 41 (44) 0.30
ETF = Early Treatment Failure; LCF = Late Clinical Failure; LPF = Late Parasitological Failure; ACPR = Adequate Clinical and Parasitological 
response.
*Comparison of proportions at follow-up survey (Fisher exact test)
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tion [15]. In a comparable study in Burkina Faso the inter-
vention was associated with a significant reduction in
malaria morbidity, but mortality was not measured [14].
However, other studies conducted in Kenya, The Gambia
and Zaire and which were using village health volunteers
for community malaria treatment were unable to show
sufficient effects of the intervention on morbidity and
mortality in young children [31-34].
In conclusion, this study has shown the feasibility of a
complex malaria community intervention which has
bridged the gap between the health workers at the periph-
eral health centres and the mothers of young children in
individual households through women groups. The cov-
erage of malaria treatment has substantially improved
during the trial. Although such an approach is promising
given the continuous lack of access to formal health serv-
ices in much of rural SSA, there was no major difference in
effectiveness between intervention and control areas. A
possible intervention effect may have been masked by
contamination, pre-existing differences in the coverage of
malaria treatment in both groups, and the rapid rise in CQ
resistance in the study area. Future studies should try to
avoid confounding influences of other malaria interven-
tions, employ more effective malaria first-line drugs such
as artemisinin-based combination therapies (ACT), and
preferably use mortality as the primary endpoint.
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